Effects of Glucagon Like Peptide-1 on No-reflow

NCT02507128 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether a medication called glucagon-like peptide-1 can reduce the risk of no-reflow, a condition where blood flow is blocked after a heart attack, in adults experiencing an acute ST-segment elevation myocardial infarction.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 190 people Planned (estimated).

Who can join Ages 18–80 · all sexes

Timeline Started 2015-07 · est. completion 2016-07

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT02507128 ↗

Description as written by the study sponsor.

The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction (STEMI).

Treatments tested

liraglutide also known as glucagon like peptide-1 Drug

Liraglutide were taken 30 min before PCI.
placebo Drug

Placebo were taken 30 min before PCI.

Main thing measured	a change in the prevalence of no-reflow
Sponsor	Chen Wei Ren, MD
Conditions studied	Acute ST-segment Elevation Myocardial Infarction
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02507128 ↗